本文已被：浏览 2293次 下载 4185次
Received:May 13, 2018 Published Online:December 20, 2018
Received:May 13, 2018 Published Online:December 20, 2018
中文摘要: 目的 探究康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗缺血性视网膜分支静脉阻塞继发复发难治性黄斑水肿的临床效果。 方法 选取2014年5月至2017年10月收治的缺血性视网膜分支静脉阻塞继发复发难治性黄斑水肿患者97例(共97只病眼)。A组(n=49)采用康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗,B组(n=48)单独采用黄斑格栅样激光光凝治疗。观察A组、B组最佳矫正视力（BCVA）指标、黄斑中心凹视网膜厚度（CMT）指标、眼底荧光血管造影（FFA）指标(荧光素局部渗漏、弥漫渗漏、囊样渗漏)。统计学检验水准取α=0.05，当采用R×C表χ2检验分割法时，校正为α′=0.0125。 结果 两组在治疗后1、3、6个月BCVA水平均较治疗前显著提高(P<0.05);与B组比较,A组在治疗后1、6个月BCVA水平均显著提高(P<0.05)。两组在治疗后1、3、6个月CMT水平均较治疗前显著提高(P<0.05);与B组比较,A组在治疗后1个月、治疗后3个月以及治疗后6个月CMT水平均显著提高(P<0.05)。两组治疗后6个月局部渗透、弥漫渗透、囊样渗透发生率与治疗前相比均显著降低(P<0.05),治疗后6个月A组局部渗透发生率明显少于B组(P<0.0125)。 结论 康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗缺血性视网膜分支静脉阻塞继发复发难治性黄斑水肿，有利于减少黄斑水肿的复发,减少对患者视网膜的损伤,有利于提高患者的生活质量。
中文关键词: 康柏西普；玻璃体腔注射 黄斑格栅样激光光凝 缺血性视网膜分支静脉阻塞 黄斑水肿
Abstract:Objective To investigate the clinical efficacy of intravitreal injection of Conbercept combined with macular grid laser photocoagulation for the treatment of recurrent macular edema due to ischemic retinal branch vein occlusion. Methods Ninety-seven patients (97 diseased eyes) with recurrent refractory macular edema secondary to ischemic retinal branch vein occlusion from May 2014 to October 2017 were selected. The patients treated with intravitreal injection of Conbercept combined with macular grid laser photocoagulation were served as group A (n=49), and the patients treated with macular grid laser photocoagulation alone were served as group B (n=48). The best corrected visual acuity (BCVA), central macular thickness (CMT) and the indexes of fundus fluorescein angiography (FFA) that is fluorescein leakage (including local leakage, diffuse leakage and cystic leakage) in two groups were observed. Results At 1-, 3- and 6-month after treatment, BCVA levels in two groups were significantly higher than those before treatment (all P<0.05). Compared with group B, the level of BCVA in group A was significantly increased at 1 month after treatment and 6 months after treatment (all P<0.05). At 1-, 3- and 6-month after treatment, BCVA levels in two groups were significantly higher than those before treatment (all P<0.05). Compared with group B, the level of BCVA in group A was significantly increased at 1 month after treatment and 6 months after treatment. At 1-, 3- and 6-month after treatment, CMT levels in two groups were significantly higher than those before treatment, and they increased significantly in group A compared with group B (all P<0.05). At six months after treatment, the incidences of fluorescein leakage (local leakage, diffuse leakage and cystic leakage) in two groups were significantly lower than those before treatment (all P<0.05) ;and the incidence of local fluorescein leakage in group A reduced significantly compared with group B (P<0.0125). Conclusion Intravitreous injection of Conbercept combined with macular grid laser photocoagulation is in favor of the reduction of recurrence of macular edema and retinal damage and improving the quality of life of patients for the treatment of recurrent refractory macular edema secondary to ischemic retinal branch vein occlusion.
keywords: Intravitreous injection of Conbercept Macular grid laser photocoagulation Ischemic retinal branch vein occlusion Macular edema
文章编号： 中图分类号： 文献标志码：A
基金项目:陕西省卫生科研项目(2014E12)
| Author Name | Affiliation |
| LIU Xiao-mao, YAN Xin-nian, FAN Qiang, ZHANG Meng, WANG Min | Department of Ophthalmology, First People′s Hospital of Xianyang, Xianyang, Shaanxi 712000, China |
| Author Name | Affiliation |
| LIU Xiao-mao, YAN Xin-nian, FAN Qiang, ZHANG Meng, WANG Min | Department of Ophthalmology, First People′s Hospital of Xianyang, Xianyang, Shaanxi 712000, China |
引用文本：